Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 17/20 | 0.48 |
| ▸ | CTSS | P25774 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1429083 | 1.00 | CA1 (0.50) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL1134628 | 0.90 | CTSK (0.52) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL5154942 | 0.86 | CA1 (0.53) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL1134626 | 0.86 | CA1 (0.53) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL1134586 | 0.86 | CA1 (0.53) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL23016026 | 0.85 | CA1 (0.56) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL20442852 | 0.85 | CA1 (0.56) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL12195048 | 0.83 | CA1 (0.50) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL13934941 | 0.83 | CA1 (0.67) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL13934324 | 0.83 | CA1 (0.67) | CA1CA2CA7CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2285785-A1 | 3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF ARWAY DISEASES | Novartis AG (CH) | 2011-02-23 | — | — | EP | disclosed |
| WO-2009138378-A1 | 3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF ARWAY DISEASES | NOVARTIS AG (CH) | 2009-11-19 | — | — | WO | disclosed |